Rocket Pharmaceuticals: Hold Rating Amid Clinical and Financial Uncertainties

Analyst Mani Foroohar from Leerink Partners reiterated a Hold rating on Rocket Pharmaceuticals and keeping the price target at $9.00.

Mani Foroohar has given his Hold rating due to a combination of factors influencing Rocket Pharmaceuticals’ current standing. The clinical hold on the pivotal trial for RP-A501 due to a patient death has created uncertainty, with no clear timeline for resumption or clarity on potential FDA requirements. While there are positive developments, such as the initial efficacy signs for RP-A601 and FDA clearance for RP-A701, the challenges in the lentiviral gene therapy partnering environment and paused developments for RP-L102 and RP-L301 add to the cautious outlook.
Financially, Rocket Pharmaceuticals reported higher than expected R&D expenses and lower SG&A costs, ending the period with a substantial cash reserve. This financial position, alongside strategic reorganization efforts, extends their cash runway, providing some stability. However, the need to resolve regulatory issues and the strategic evaluation of paused projects contribute to the Hold rating, reflecting a balanced view of potential risks and opportunities.

Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, Moderna, and Rocket Pharmaceuticals. According to TipRanks, Foroohar has an average return of -8.3% and a 42.53% success rate on recommended stocks.

In another report released yesterday, Evercore ISI also maintained a Hold rating on the stock with a $5.00 price target.